Posted by Michael Wonder on 26 Oct 2019
Public sector financial support for late stage discovery of new drugs in the United States: cohort study
23 October 2019 - This study determined the extent to which late stage development of new drugs relies on support from public funding.
The study sample was all new drugs containing one or more new molecular entities approved by the US FDA between January 2008 and December 2017 via the new drug application pathway.
Over the 10 year study period, the FDA approved 248 drugs containing one or more new molecular entities. Of these drugs, 48 (19%) had origins in publicly supported research and development and 14 (6%) originated in companies spun off from a publicly supported research program.
